Baseline characteristics
Characteristics . | Treated, n = 83 . | Untreated, n = 68 . | P . |
|---|---|---|---|
| Age, y (IQR) | 35 (30-40) | 34 (30-41) | .97 |
| Sex, % | 94 | 96 | .73 |
| Infection stage, % | .001 | ||
| Less than 30 d | 24.1 | 2.9 | |
| 1 to 6 mo | 71.1 | 88.2 | |
| 6 to 12 mo | 4.8 | 8.8 | |
| Presence of one or more drug-resistance associated mutations, % | 17.4 | 17.8 | 1.0 |
| HIV risk factors, % | |||
| MSM | 94.0 | 100 | .07 |
| Intravenous drug user | 4.4 | 2.4 | 1.0 |
| CD4+ T-cell count, cells/mm3 (IQR) | 484 (374-646) | 539 (451-717) | .03 |
| CD8+ T-cell count, cells/mm3 (IQR) | 798 (572-1071) | 817 (632-1086) | .68 |
| Plasma HIV RNA level, log10 copies RNA/mL | 5.10 (4.18-5.63) | 4.26 (3.36-4.70) | < .0001 |
| Baseline CD4+ CD38, relative fluorescence units | 33.2 (23.3-46.4) | 19.7 (8.2-41.4) | .004 |
| Baseline CD8+ CD38, relative fluorescence units | 99.6 (39.6-256) | 33.4 (9.8-67.6) | < .0001 |
Characteristics . | Treated, n = 83 . | Untreated, n = 68 . | P . |
|---|---|---|---|
| Age, y (IQR) | 35 (30-40) | 34 (30-41) | .97 |
| Sex, % | 94 | 96 | .73 |
| Infection stage, % | .001 | ||
| Less than 30 d | 24.1 | 2.9 | |
| 1 to 6 mo | 71.1 | 88.2 | |
| 6 to 12 mo | 4.8 | 8.8 | |
| Presence of one or more drug-resistance associated mutations, % | 17.4 | 17.8 | 1.0 |
| HIV risk factors, % | |||
| MSM | 94.0 | 100 | .07 |
| Intravenous drug user | 4.4 | 2.4 | 1.0 |
| CD4+ T-cell count, cells/mm3 (IQR) | 484 (374-646) | 539 (451-717) | .03 |
| CD8+ T-cell count, cells/mm3 (IQR) | 798 (572-1071) | 817 (632-1086) | .68 |
| Plasma HIV RNA level, log10 copies RNA/mL | 5.10 (4.18-5.63) | 4.26 (3.36-4.70) | < .0001 |
| Baseline CD4+ CD38, relative fluorescence units | 33.2 (23.3-46.4) | 19.7 (8.2-41.4) | .004 |
| Baseline CD8+ CD38, relative fluorescence units | 99.6 (39.6-256) | 33.4 (9.8-67.6) | < .0001 |
Median and interquartile ranges (IQRs) are shown. MSM indicates men who have sex with men.